Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference

SEATTLE, Jan. 22, 2018 /PRNewswire/ -- Kineta Immuno-oncology, LLC, a biotechnology company focused on developing disruptive technologies to turn cold tumors hot, today announced that they have been invited to present at the Immuno-Oncology Frontiers World Conference sponsored by Phacilitate.  Dr. Kristin Bedard, Kineta Immuno-oncology Chief Scientific Officer, will present at 2:50PM EST on January 24, 2018. The conference takes place on January 22-25 at the Hyatt Regency Hotel in Miami, FL.

Dr. Bedard will present on the proof of concept compound, KIN131A, which activates RIG-I-dependent signaling to stimulate chemokine/cytokine production by human PBMCs, and induces direct activation of dendritic cells. In colon carcinoma cells, KIN131A treatment induces the intrinsic apoptosis pathway and triggers immunogenic cell death (ICD) in a RIG-I dependent manner. Additionally, in vivo experiments demonstrated tumor immunity as KIN131A inhibits tumor growth, enhances survival and causes complete regression of tumor growth in approximately 30% of mice. Mice showing complete tumor regression were resistant to re-challenge up to 6 months after primary tumor implantation. Animals that were responsive to KIN131A treatment also demonstrated an increase in tumor antigen specific T cells compared to tumor bearing animals.

"These data demonstrate that the RIG-I agonists activate the innate immune response, induce ICD in tumor cells in vivo and elicit an anti-tumor memory T cell response controlling tumor growth," said Dr. Bedard.  "The induction of ICD by small molecule RIG-I agonists may provide a unique immunotherapeutic opportunity to induce or boost the antitumor immune response in patients and enhance the efficacy of checkpoint inhibitor-mediated immunotherapy."

Kineta, Immuno-Oncology is a privately held biotech company focused on developing disruptive technologies that shift the paradigm in cancer treatment by turning cold tumors hot.  Our research and development is centered around small molecule innate immune activators of the RIG-I pathway.  This novel pathway has been largely unexploited for drug discovery.  Activating innate immune pathways can cause direct tumor killing and an anti-tumor immune response.

Kineta Immuno-oncology was established in 2016.  Our novel technology was originally discovered through the innate immune screening platform developed by Kineta, Inc. and supported by funding from the National Institutes of Health (NIH).  For more information on Kineta, Inc. visit our website at www.kinetaimmuno-oncology.com.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta Immuno-oncology's plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta Immuno-oncology's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta Immuno-oncology undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy
[email protected]
(206) 378-0400

SOURCE Kineta Immuno-oncology